Office of the Associate Director (OAD)
DTP provides resources and services to both public and private research communities, maintains a robust infrastructure for anti-cancer drug discovery and development, and manages a large portfolio of grants pertinent to drug discovery and biochemical pharmacology. Upon request, DTP also provides advices on drug development issues regarding chemistry, manufacturing & control, pharmacology & toxicology, and IND requirements.
DTP/OAD provides planning, implementation, coordination and oversight for all DTP activities.
|Dr. Jerry M. Collins||Associate Directoremail@example.com|
|Dr. Min He||Special Assistant to DTP Associate Directorfirstname.lastname@example.org|
|Dr. Brian D. Peyser||Special Assistant to DTP Associate Directoremail@example.com|
|Dr. Michael Currens||Special Assistant to DTP Associate Directorfirstname.lastname@example.org|
|Bernadette Carter||Program Assistantemail@example.com|
Jerry M. Collins, Ph.D., is an internationally recognized pharmacologist. He has been closely associated with NCI’s drug development efforts for more than 25 years, first as an NCI intramural investigator and then as the Chief of the Pharmacokinetics Section. More…